Genomics In Cancer Care Market Analysis
The genomics in the cancer care market stood at USD 21.07 billion in 2024 and is forecast to reach USD 52.15 billion by 2030, advancing at a 16.3% CAGR. The surge reflects sustained technology innovation, harmonized regulation, and expanding clinical validation that make genomic testing central to precision oncology. Broader Medicare reimbursement for liquid biopsy, falling sequencing costs that bring whole-genome testing close to the USD 100 threshold, and rapid integration of artificial-intelligence decision tools are reshaping therapeutic strategies toward proactive, molecularly guided care. Competitive intensity accelerates as platform vendors converge with analytics specialists, and as single-molecule, real-time sequencing begins to erode short-read NGS dominance. Together, these dynamics reinforce a structural transition from one-off diagnostic assays to longitudinal, data-rich solutions that inform every stage of the oncology journey.
Key Report Takeaways
- By product type, instruments led with 38.2% revenue share in 2024, while services are projected to grow at an 18.7% CAGR through 2030.
- By technology, genome sequencing commanded 46% of the genomics in cancer care market share in 2024, and single-molecule real-time sequencing is advancing at a 23.4% CAGR to 2030.
- By application, diagnostics held 52.4% of the genomics in cancer care market size in 2024; minimal-residual-disease monitoring and liquid biopsy is expanding at a 21.1% CAGR.
- By end-user, hospitals and cancer centers accounted for 41.7% of the genomics in cancer care market size in 2024, while reference and clinical laboratories are rising at a 17.6% CAGR.
- By geography, North America contributed 37.1% market share in 2024, and Asia-Pacific posted the fastest regional CAGR at 14.8%.
Global Genomics In Cancer Care Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Growing burden of cancer & earlier screening | +3.20% | Global, concentrated in North America & Europe | Medium term (2-4 years) |
| Increasing adoption of NGS-based CGP | +4.10% | North America & EU, expanding to Asia-Pacific | Short term (≤ 2 years) |
| Rapid sequencing and digital-PCR cost decline | +2.80% | Global, accelerated in emerging markets | Long term (≥ 4 years) |
| Scaling liquid-biopsy MRD pipelines | +3.50% | North America & EU, early expansion in Asia-Pacific | Medium term (2-4 years) |
| AI-powered multi-omic decision tools | +1.90% | North America & EU, limited penetration in emerging markets | Long term (≥ 4 years) |
| Rise of reimbursement for tumor-agnostic CDx | +2.40% | North America & EU, gradual adoption in Asia-Pacific | Medium term (2-4 years) |
| Source: | |||
Growing Burden of Cancer & Earlier Screening Programs
Robust growth in global cancer incidence is compelling health-system planners to shift resources toward preventive genomic screening. Latin America alone projects a 66% rise in cancer cases by 2040, intensifying pressure to catch malignancies at sub-clinical stages. U.S. agencies embraced blood-based detection when the FDA cleared Guardant Health’s Shield test for colorectal screening in adults aged 45 and older, setting a precedent for non-invasive assays.[1]U.S. Food and Drug Administration, “FDA Takes Action to Ensure Safety and Effectiveness of Laboratory Developed Tests,” fda.gov Large population trials such as the National Cancer Institute’s Vanguard study employ the same platform to test multi-cancer detection across diverse cohorts. These developments create long-term reimbursement pathways, foster payer confidence, and bolster recurring revenue streams for test developers while lowering downstream treatment costs.
Increasing Adoption Of NGS-Based Comprehensive Genomic Profiling
Oncology practices are migrating from sequential single-gene tests toward expansive panels that interrogate hundreds of loci in one run. Evidence from the GOZILA trial showed patients guided by the Guardant360 CDx liquid biopsy achieved a median overall survival of 18.6 months compared with 9.9 months under standard care. Illumina’s TruSight Oncology Comprehensive became the first FDA-cleared kit with pan-cancer companion-diagnostic claims.
Rapid Cost Decline of Sequencing & Digital PCR Reagents
PacBio’s SPRQ chemistry for Revio systems cut HiFi whole-genome sequencing costs below USD 500 while preserving accuracy. The University of Minnesota Genomics Center reported an additional 20% drop after adopting AVITI technology, surpassing Illumina NovaSeq X Plus on cost-per-gigabase metrics. Roche’s sequencing-by-expansion prototypes promise throughput capable of seven 30× human genomes per hour. These breakthroughs help institutions in emerging economies overcome budget barriers and lay the groundwork for point-of-care genomic testing models.
Scaling Liquid-Biopsy Pipelines for Minimal-Residual-Disease (MRD) Monitoring
Exact Sciences’ OncoDetect test identifies colorectal-cancer recurrence up to two years earlier than imaging by scanning 200 ctDNA variants. A 2,000-patient colon-cancer study showed 62.6% of ctDNA-positive cases relapsed within three years versus 15.4% of ctDNA-negative cases, reinforcing MRD’s prognostic power. The FDA guidance on ctDNA endpoints sponsors use liquid biopsy for accelerated approval pathways.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Shortage Of Accredited Molecular Pathologists | -2.10% | Global, with acute shortages in emerging markets | Long term (≥ 4 years) |
| Persistently High Total-Cost-Of-Ownership For WGS Platforms | -1.80% | Global, with disproportionate impact on emerging markets | Medium term (2-4 years) |
| Cyber-Security & Genomic-Data-Sovereignty Regulation | -1.30% | North America & EU core, expanding to APAC | Medium term (2-4 years) |
| Limited Clinical-Utility Evidence For Emerging MRD Assays | -0.90% | Global, with regulatory focus in North America & EU | Short term (≤ 2 years) |
| Source: | |||
Shortage Of Accredited Molecular Pathologists
Worldwide demand for professionals who can translate multi-omic data into clinical action far exceeds supply. Training requirements encompass molecular biology, bioinformatics, and oncology subspecialties, competencies that extend beyond legacy pathology curricula. Emerging economies face added challenges as talent migrates to higher-income regions. AI tools lighten routine interpretation workloads, yet regulations still require board-certified oversight for final sign-off. Fast-track certification programs are under development, but workforce expansion will lag market growth for several years.
Persistently High Total-Cost-Of-Ownership for WGS Platforms
While reagent costs keep falling, capital outlays for high-throughput sequencers, environmental controls, secure data storage, and specialized staffing remain steep. Mid-sized hospitals in emerging economies must often send samples to external reference labs, slowing turnaround and limiting the accrual of in-house expertise. Cloud bioinformatics services reduce hardware needs, but data-sovereignty rules and cybersecurity obligations raise separate compliance expenses. Sequencing-as-a-service models continue to mature, yet have not fully resolved budget constraints.
Segment Analysis
By Product Type: Services Drive Growth Despite Instruments Dominance
Instruments represented the largest revenue pool, holding 38.2% share of the genomics in the cancer care market in 2024. Demand reflected ongoing platform refresh cycles as users swapped legacy sequencers for higher-throughput, longer-read systems. Consumables sales expanded in line with test-volume growth, while point-of-care cartridges opened new, decentralized channels.
Services are accelerating at an 18.7% CAGR, underscoring a shift toward data interpretation, cloud analytics, and integrated clinical reporting. Guardant Health’s 31% revenue jump to USD 737 million during 2024 shows the pull of recurring testing and bioinformatics fees. Hospitals increasingly outsource bioinformatics to mitigate staffing shortages, and bundled, end-to-end service contracts now cover sample logistics, sequencing, interpretation, and decision-support updates. This evolution positions service providers as strategic partners rather than transactional suppliers within the genomics in cancer care market.
By Technology: Single-Molecule Sequencing Disrupts NGS Dominance
Genome sequencing platforms based on short-read NGS secured 46% market share in 2024, supported by established laboratory workflows and extensive clinical evidence. Yet single-molecule, real-time sequencing is expanding at a startling 23.4% CAGR as oncologists seek structural-variant resolution in repeat-rich regions and methylation layers unavailable from short reads.
Oxford Nanopore’s latest chemistry generated complete chromosome assemblies and simultaneous epigenetic maps, demonstrating the clinical readiness of long-read approaches. Meanwhile, Roche’s sequencing-by-expansion prototypes promise to merge long reads with high throughput, threatening to redraw product-replacement cycles. PCR-based kits retain value for low-plex companion diagnostics and rapid EGFR or KRAS checks, yet microarrays are ceding ground as sequencing prices near parity. Technology diversity ensures that laboratories can align platform choice with specific oncology use cases inside the genomics in cancer care market.
By Application: MRD Monitoring Accelerates Beyond Diagnostics
Diagnostics maintained 52.4% of the genomics in the cancer care market size in 2024 through entrenched companion-diagnostic pathways and payer familiarization. Routine EGFR, BRAF, and PIK3CA panels anchor laboratory revenue streams.
Minimal-residual-disease and liquid-biopsy assays, growing at a 21.1% CAGR, are redefining follow-up protocols. The SERENA-6 trials verified that ctDNA-guided treatment switches halve the progression risk for ER-positive breast-cancer patients with emergent ESR1 mutations. Pharma sponsors now embed MRD endpoints in adjuvant-therapy trials, which reinforce assay volumes post-approval. Drug-discovery genomics and precision-oncology decision platforms further enlarge the pipeline, supplying biomarker insights during early clinical development and supporting adaptive trial designs.
By End-user: Reference Labs Gain Share Through Specialized Capabilities
Hospitals and cancer centers generated 41.7% of 2024 revenue, leveraging on-site pathology and integrated care teams to run high-throughput panels for newly diagnosed patients. Yet reference and clinical laboratories exhibit the fastest momentum at 17.6% CAGR, bolstered by economies of scale and capital-intensive automation that lower per-sample costs.
Labcorp’s partnership with Ultima Genomics to expand whole-genome offerings and to launch Plasma Detect ctDNA MRD illustrates reference labs’ strategic positioning. Pharmaceutical and biotech firms intensify demand for high-complexity assays to stratify trial subjects, while academic institutes pilot novel technologies before broader rollout. Together, these segments create a complementary ecosystem in which centralized expertise coexists with bedside sequencing in the genomics market for cancer care.
Geography Analysis
North America led with 37.1% market share in 2024, supported by broad payer coverage, a mature clinical-trial network, and stringent but predictable regulatory oversight. The FDA’s May 2024 Laboratory Developed Tests final rule aligned quality requirements across commercial and academic laboratories. Parallel Medicare decisions extended reimbursement to liquid-biopsy-based MRD surveillance, unlocking sizable, recurring test volumes. Cross-industry collaborations ensure rapid migration of research innovations into front-line clinical practice, consolidating the region’s leadership in the genomics in cancer care market.
Asia Pacific records the fastest regional CAGR at 14.8% to 2030. National genome programs in China, Japan, Singapore, and the United Arab Emirates underpin large-scale sequencing infrastructure and create fertile ground for early screening pilots. Ongoing investment in Saudi Arabia’s precision-medicine corridor, combined with streamlined regulatory pathways in the United Arab Emirates, attracts multinational diagnostics firms to establish regional hubs. Rising cancer incidence and widening insurance coverage accelerate demand, while local manufacturing partnerships drive down consumables’ costs, improving accessibility.
Europe remains a critical pillar of global adoption through coordinated regulatory and value-assessment frameworks. The European Commission’s conditional approval of Illumina’s divestment plan for GRAIL removed a legal logjam, restoring competitive balance and allowing pan-European multi-cancer screening pilots to proceed. Meanwhile, the EU In Vitro Diagnostic Regulation enforces stringent clinical-evidence requirements, boosting confidence among physicians and payers. Standard-setting bodies such as the European Liquid Biopsy Society publish harmonized protocols that foster reproducibility across laboratories. In combination, these measures sustain healthy growth despite mature infrastructure.
Competitive Landscape
The genomics in the cancer care market is moderately consolidated. Illumina, Thermo Fisher Scientific, and Roche hold multi-platform portfolios that span instruments, consumables, and software, granting them pricing leverage and global distribution reach. Specialized providers such as Guardant Health and Exact Sciences outpace the field in liquid-biopsy and MRD niches, leveraging protected assay patents and large proprietary datasets.
Mergers and acquisitions intensified in 2024–2025 as incumbents sought AI analytics, multi-omic fusion capabilities, and regional market entry.
Examples include Guardant Health’s agreement with Pfizer to co-develop therapy-linked diagnostics and PacBio’s release of the benchtop Vega system aimed at decentralizing HiFi sequencing. Litigation has also emerged as a competitive instrument; Guardant filed suit against Tempus AI alleging infringement of DNA-testing patents.
Players are now prioritizing vertical integration, pairing wet-lab kits with real-time analytics delivered through cloud dashboards. Intellectual-property filings concentrate on chemistry that improves read accuracy and on machine-learning pipelines that cut interpretation time. Emerging white spaces include point-of-care sequencing for community oncology clinics, AI-driven molecular tumor boards, and turnkey solutions tailored to low-resource settings.
Recent Industry Developments
- May 2025: Guardant Health introduced Guardant360 Tissue, a multi-omic tissue profile that delivers results in under two weeks and uses 40% less material than conventional workflows.
- April 2025: Exact Sciences released the OncoDetect MRD assay, which detects up to 200 ctDNA variants and flags recurrence up to two years earlier than imaging.
- April 2025: Exact Sciences released the OncoDetect MRD assay, which detects up to 200 ctDNA variants and flags recurrence up to two years earlier than imaging.
- January 2025: Guardant Health and ConcertAI launched the first data-as-a-service platform integrating 5.5 million clinical records with tumor-profiling data across more than 60 cancer types.
- November 2024: PacBio unveiled the benchtop Vega system, extending HiFi sequencing to smaller laboratories.
